End-Stage Renal Disease - Pipeline Insight, 2025

DelveInsight’s, “End-Stage Renal Disease - Pipeline Insight, 2025” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in End-Stage Renal Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

End-Stage Renal Disease: Understanding

End-Stage Renal Disease: Overview

End-stage renal disease (ESRD) is a severe and irreversible decline in kidney function that is fatal without dialysis or transplantation. It is characterized by a glomerular filtration rate (GFR) of less than 15 mL per minute per 1.73 m² body surface area, which is significantly lower than the typical kidney function of 90 mL per minute per 1.73 m². ESRD is a common complication of chronic kidney disease (CKD), which can be caused by various factors such as advanced age, hypertension, diabetes mellitus, obesity, a history of renal disease, and substance abuse like tobacco, heroin, or analgesics. The condition is associated with a range of maladaptive changes, including fluid retention, anaemia, disturbances of bone and mineral metabolism, dyslipidaemia, and protein energy malnutrition, which can contribute to increased cardiovascular risk and mortality.

End-stage renal disease (ESRD) is characterized by a wide range of symptoms that can vary in severity and impact quality of life. Common symptoms include fatigue, drowsiness, decreased urination or inability to urinate, dry and itchy skin, headaches, weight loss, nausea, bone pain, and changes in skin and nail appearance. Additionally, patients may experience numbness in the hands and feet, difficulty concentrating, and easy bruising. In some cases, patients may also experience chest pain due to fluid buildup around the heart, shortness of breath from fluid accumulation in the lungs, and swelling in the feet and ankles. These symptoms are often nonspecific and can be caused by other illnesses, making it essential to monitor kidney function through regular blood and urine tests to diagnose ESRD early and initiate appropriate treatment.

The treatment of end-stage renal disease (ESRD) primarily involves kidney transplantation or dialysis. Kidney transplantation is often the preferred treatment, as it can provide the best long-term outcomes for patients. However, due to the limited availability of donor kidneys, most patients with ESRD are treated with dialysis, either hemodialysis or peritoneal dialysis. Dialysis helps to remove waste products and excess fluid from the body, but it is associated with various complications and a high mortality rate. For patients who are not candidates for transplantation or dialysis, a palliative approach focused on symptom management and quality of life may be a reasonable alternative. Regardless of the treatment approach, managing the associated comorbidities, such as hypertension, diabetes, and cardiovascular disease, is crucial to optimize patient outcomes.

""End-Stage Renal Disease - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the End-Stage Renal Disease pipeline landscape is provided which includes the disease overview and End-Stage Renal Disease treatment guidelines. The assessment part of the report embraces, in depth End-Stage Renal Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, End-Stage Renal Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence End-Stage Renal Disease R&D. The therapies under development are focused on novel approaches to treat/improve End-Stage Renal Disease.

End-Stage Renal Disease Emerging Drugs Chapters

This segment of the End-Stage Renal Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II/III, II, I, preclinical and discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

End-Stage Renal Disease Emerging Drugs

• AB002: Aronora

The company’s lead product candidate, AB002 (E-WE thrombin), is a first-in-class protein C activator enzyme. AB002 has been designed to act in part by increasing the surface concentration of the anticoagulant, profibrinolytic, and cytoprotective enzyme, endogenous activated protein C (APC), at the site of developing blood clots via targeted cellular delivery. This unique mechanism of action allows AB002 to target cell-rich pathological blood clots (thrombi) without disabling vital hemostasis. AB002 received FDA Fast Track designation. The drug is currently being evaluated under Phase II clinical trial for the treatment of patients with End-Stage Renal Disease.

• Apabetalone: Resverlogix Corporation

Apabetalone (RVX-208), is a first-in-class, small molecule, therapeutic candidate with an epigenetic mechanism of action. It is a BD2 (bromodomain) selective BET (bromodomain and extra-terminal) inhibitor that works in preventing and treating disease by regulating the expression of disease-causing genes. The drug is currently being evaluated under Phase I/II clinical trial for the treatment of patients with End-Stage Renal Disease.

Further product details are provided in the report……..

End-Stage Renal Disease: Therapeutic Assessment

This segment of the report provides insights about the different End-Stage Renal Disease drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in End-Stage Renal Disease

There are approx. 4+ key companies which are developing the therapies for End-Stage Renal Disease. The companies which have their End-Stage Renal Disease drug candidates in the most advanced stage, i.e. Phase II include, Aronora.

• Phases

DelveInsight’s report covers around 4+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

End-Stage Renal Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

End-Stage Renal Disease: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses End-Stage Renal Disease therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging End-Stage Renal Disease drugs.

End-Stage Renal Disease Report Insights

• End-Stage Renal Disease Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

End-Stage Renal Disease Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing End-Stage Renal Disease drugs?
• How many End-Stage Renal Disease drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of End-Stage Renal Disease?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the End-Stage Renal Disease therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for End-Stage Renal Disease and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Aronora
• Resverlogix Corporation
• Vascular Therapies

Key Products

• AB002
• Apabetalone
• Sirogen